Eli Lilly's new diabetes drug continues to show promise as an obesity treatment
1 min read
Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.
2022-06-07 17:33:57
All news and articles are copyrighted to the respective authors and/or News Broadcasters. VIXC.Com is an independent Online News Aggregator
Read more from original source here…
